Money Concepts Capital’s CRISPR Therapeutics CRSP Stock Holding History

Money Concepts Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$225K	Buy	+4,738	New	+$250K	0.01%	521
2025 Q3	–	Sell	-4,885	Closed	-$238K	–	474
2025 Q2	$238K	Buy	+4,885	New	+$189K	0.02%	405
2023 Q1	–	Sell	-4,118	Closed	-$167K	–	960
2022 Q4	$167K	Buy	4,118 +150	+4%	+$7.96K	0.01%	765
2022 Q3	$259K	Buy	3,968 +3,912	+6,986%	+$284K	0.02%	384
2022 Q2	$4K	Sell	56 -205	-79%	-$12.1K	﹤0.01%	1200
2022 Q1	$16K	Buy	+261	New	+$16.4K	﹤0.01%	1706

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Money Concepts Capital's CRSP Position: Q1 2026 in Review

Money Concepts Capital opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 4,738 shares worth $225K. The stake represents 0.01% of the portfolio and ranks #521 among its holdings. This is a return to the name: Money Concepts Capital previously reported a position in CRSP as recently as Q2 2025.

Money Concepts Capital first reported a position in CRSP in Q1 2022 and has held it in 6 quarters since. The position peaked at $259K in Q3 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Money Concepts Capital held 4,738 shares of CRISPR Therapeutics worth $225K as of Q1 2026.
CRISPR Therapeutics was a new Money Concepts Capital position in Q1 2026.
CRISPR Therapeutics made up 0.01% of Money Concepts Capital's portfolio in Q1 2026, its #521 holding.
Money Concepts Capital first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 6 quarters since.
Money Concepts Capital's CRISPR Therapeutics position peaked at $259K in Q3 2022.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Money Concepts Capital's 13F filing for Q1 2026, filed 30 Apr 2026.